Unavailable
Unavailable
Save time and jump to the most important pieces.
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company's common stock will trade on a post-split basis un
SARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, proudly supports the U.S. President's recent executive order aimed at reducing the cost of IVF and expanding access to fertility services. The order directs the Domestic Policy Council to develop policy recommendations within 90 days to protect IVF access and significantly lower out-of-pocket expenses and health plan costs for
New board reflects company's added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025. Laurent Audoly, PhD is the cofounder and CEO of PriveBio, a precision medicine company, and a professor and strategic advisor at the Institute for Experient
SC 13G/A - NAYA Biosciences, Inc. (0001417926) (Subject)
8-K - NAYA Biosciences, Inc. (0001417926) (Filer)
DEFR14A - NAYA Biosciences, Inc. (0001417926) (Filer)
8-K - NAYA Biosciences, Inc. (0001417926) (Filer)